Our broad pipeline includes four product candidates for targeted medicines and immune-oncology therapies.
CBT-101 is an oral agent that targets the epithelial to mesenchymal transition (EMT) pathway that is dysregulated in several tumors. It is a specific inhibitor of the c-Met receptor.
CBT-102 is a potent inhibitor of the MAP Kinase pathway by affecting b-RAF and c-RAF kinases as well as an inhibitor of angiogenesis by affecting the VEGF and PDGF receptors.
CBT-501 is a novel IgG4 humanized monoclonal antibody against the Programmable Death-1 (PD-1) membrane receptor on immune cells with world-wide rights retained by CBT Pharmaceuticals, Inc. and China rights granted to Genor BioPharma.
CBT-502 is a novel IgG4 humanized monoclonal antibody against the Programmable Death Ligand-1 (PDL-1) membrane receptor on tumor cells with world-wide rights granted to CBT Pharmaceuticals, Inc. and China rights granted to Chia Tai TianQing (CTTQ).
Disclaimer: Safety and efficacy of the aforementioned compounds have not been established.